PROSTIN F2 ALPHA Drug Patent Profile

Which patents cover Prostin F2 Alpha, and when can generic versions of Prostin F2 Alpha launch?

Prostin F2 Alpha is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in PROSTIN F2 ALPHA is dinoprost tromethamine. There are six drug master file entries for this compound. Additional details are available on the dinoprost tromethamine profile page.

Summary for PROSTIN F2 ALPHA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROSTIN F2 ALPHA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	PROSTIN F2 ALPHA	dinoprost tromethamine	INJECTABLE;INJECTION	017434-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for PROSTIN F2 ALPHA

See the table below for patents covering PROSTIN F2 ALPHA around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	767926
Switzerland	563329
Switzerland	563330

Investment Scenario and Fundamentals Analysis for PROSTIN F2 ALPHA

Last updated: February 13, 2026

What Is PROSTIN F2 ALPHA?

PROSTIN F2 ALPHA (dinoprostone) is a prostaglandin E2 derivative used clinically to induce labor, terminate pregnancy, and manage postpartum hemorrhage. It is marketed in multiple formulations, including gels, inserts, and suppositories. The drug is administered primarily in obstetrics and gynecology settings.

Market Overview and Size

The global prostin market, primarily driven by dinoprostone products, was valued at approximately $300 million in 2022. The market is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years. Growth drivers include:

• Increasing maternal healthcare spending.
• Rising cesarean section rates (which increase the need for labor induction).
• Expanding use in postpartum hemorrhage management.

Major regions include North America (45%), Europe (25%), Asia-Pacific (20%), and rest of the world (10%).

Key Players and Competitive Landscape

Leading manufacturers include:

• Ferring Pharmaceuticals (Brisbane, Australia): Market leader with a broad portfolio.
• Pfizer: Offers proprietary formulations.
• Watson Pharmaceuticals: Focuses on generics.
• Others include Mylan and Sandoz, especially in the generics segment.

Market share distribution is uneven, with Ferring capturing approximately 40% of sales globally.

Patent and Regulatory Status

PROSTIN F2 ALPHA's patents have expired in most markets, leading to increased generic manufacturing. Regulatory approvals are held by health authorities such as the FDA, EMA, and WHO prequalification. Patent expirations have facilitated market penetration by generics, leading to price erosion.

Patent Landscape and Patent Expiry

• The original patent expiration occurred around 2015-2018.
• Multiple generic versions approved since then.
• No active patent protection for proprietary formulations available.

Pricing and Reimbursement

Pricing varies geographically:

• U.S.: Prices range between $15 and $50 per dose, depending on formulation.
• Europe: Similar range, with some countries providing reimbursement.
• Emerging markets: Lower prices ($5–$15), often with government reimbursement programs.

Reimbursement policies heavily influence market penetration and profit margins.

Investment Fundamentals

Revenue Streams

• Product sales from branded and generic formulations.
• Opportunities in hospital procurement, especially for postpartum hemorrhage management, where the drug is essential.

Cost Structure

• Manufacturing costs are low due to generic production (estimated at <$1 per dose).
• Distribution costs vary, with higher expenses in emerging markets.
• R&D costs are minimal compared to new drug development, as formulations are well established.

Growth Drivers

• Increasing obstetric procedures globally.
• Supply chain expansions into emerging markets.
• Potential for new delivery systems tailored to specific populations.

Risks

• Price erosion following patent expiry.
• Regulatory barriers in certain markets.
• Competition from alternative labor induction methods like misoprostol and oxytocin.
• Strict clinical guidelines potentially limiting off-label use.

Key Opportunities and Challenges

• Growth in developing nations due to improved healthcare infrastructure.
• Opportunities for new delivery formats (e.g., sustained-release inserts).
• Challenges from competing drugs, notably misoprostol, which offers oral administration and lower cost.

Financial Trends and Projections

Most companies manufacturing PROSTIN F2 ALPHA report stable or declining revenues for the core product due to generic competition. Strategic shifts include diversifying into new formulations and markets.

---

Key Takeaways

• PROSTIN F2 ALPHA is a mature, widely used obstetric drug with declining profits in generic markets.
• Growth potential exists in emerging markets and through innovation in delivery systems.
• Price erosion and competition limit upside in developed markets.
• Regulatory and patent expiration statuses heavily influence market dynamics.
• Strategic opportunities include expanding indications and delivery methods.

---

FAQs

1. What are the main competitors to PROSTIN F2 ALPHA?
Misoprostol (typically used off-label for labor induction) and oxytocin are primary alternatives, especially in resource-limited settings.

2. How does patent expiration affect investment prospects?
Patent expiry allows generic manufacturers to enter the market, reducing prices and profit margins for branded versions, which pressures revenues.

3. Are there new formulations or delivery methods in development?
Yes, research focuses on sustained-release inserts and alternative delivery systems to improve efficacy and patient compliance.

4. What is the regulatory outlook for expanding PROSTIN F2 ALPHA’s approved uses?
Regulatory agencies are cautious, requiring substantial clinical evidence. Current approved uses are well established, with limited scope for expansion without new trials.

5. How sensitive is the market to pricing changes?
Highly sensitive, particularly in price-competitive regions where generic competition dominates; pricing directly influences market share and profitability.

---

References

[1] "Global Prostaglandins Market," ReportLinker, 2022.
[2] "Dinoprostone (PROSTIN F2 ALPHA) Market Analysis," MarketsandMarkets, 2023.
[3] U.S. Food and Drug Administration, Labeling for Dinoprostone, 2021.
[4] "Patent Status and Generic Entry in Obstetric Drugs," PatentScope, WIPO, 2022.